We are live on ! Find out more
AIMT

Aimmune Therapeutics
AIMT

Delisted

AIMT was delisted on the 12th of October, 2020.

Back to rankings

165 hedge funds and large institutions have $824M invested in Aimmune Therapeutics in 2020 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 72 increasing their positions, 37 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

95% more repeat investments, than reductions

Existing positions increased: 72 | Existing positions reduced: 37

69% more call options, than puts

Call options by funds: $8.66M | Put options by funds: $5.11M

18% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 22

16% more capital invested

Capital invested by funds: $712M → $824M (+$113M)

2% more funds holding

Funds holding: 161 → 165 (+4)

Holders
165
Holders Change
+4
Holders Change %
+2.48%
% of All Funds
3.38%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
26
Increased
72
Reduced
37
Closed
22
Calls
$8.66M
Puts
$5.11M
Net Calls
+$3.55M
Net Calls Change
+$2.3M

Top Buyers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
+$25.9M
2
First Manhattan
First Manhattan
New York
+$17.4M
3
AC
Armistice Capital
New York
+$5.5M
4
SCA
Southpoint Capital Advisors
New York
+$5.09M
5
BlackRock
BlackRock
New York
+$5.03M

Top Sellers

Rank Fund Capital Flow
1
Victory Capital Management
Victory Capital Management
Texas
-$28.9M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$13.1M
3
Morgan Stanley
Morgan Stanley
New York
-$11.3M
4
EAM
Eventide Asset Management
Massachusetts
-$11.2M
5
NCM
Nantahala Capital Management
Connecticut
-$8.01M
Name Holding Trade Value Shares
Change 		Change in
Stake
SG Americas Securities
51
SG Americas Securities
New York
$2.48M +$2.38M +140,040 +1,735%
California Public Employees Retirement System
52
California Public Employees Retirement System
California
$1.72M +$50.3K +2,960 +3%
TD Asset Management
53
TD Asset Management
Ontario, Canada
$1.68M +$47.5K +2,800 +3%
ACM
54
Asymmetry Capital Management
California
$1.68M +$1.71M +100,544 New
Swiss National Bank
55
Swiss National Bank
Switzerland
$1.55M +$324K +19,100 +26%
FMBTD
56
First Midwest Bank Trust Division
Illinois
$1.52M +$99.3K +5,851 +7%
RhumbLine Advisers
57
RhumbLine Advisers
Massachusetts
$1.49M +$198K +11,653 +15%
UBS Group
58
UBS Group
Switzerland
$1.42M +$381K +22,435 +36%
Citigroup
59
Citigroup
New York
$1.4M +$534K +31,425 +60%
MWNA
60
Marshall Wace North America
New York
$1.34M +$1.37M +80,514 New
Barclays
61
Barclays
United Kingdom
$1.3M -$164K -9,681 -11%
Two Sigma Advisers
62
Two Sigma Advisers
New York
$1.25M +$730K +43,000 +134%
AllianceBernstein
63
AllianceBernstein
Tennessee
$1.21M – – –
PPA
64
Parametric Portfolio Associates
Washington
$1.21M +$255K +15,003 +26%
California State Teachers Retirement System (CalSTRS)
65
California State Teachers Retirement System (CalSTRS)
California
$1.17M +$36.3K +2,139 +3%
State of Wisconsin Investment Board
66
State of Wisconsin Investment Board
Wisconsin
$1.17M +$10.2K +600 +0.9%
Baird Financial Group
67
Baird Financial Group
Wisconsin
$1.1M +$461K +27,171 +70%
Squarepoint
68
Squarepoint
New York
$1.07M +$1.09M +64,060 New
BAM
69
Bullseye Asset Management
Colorado
$969K +$248K +14,615 +34%
Russell Investments Group
70
Russell Investments Group
United Kingdom
$927K +$105K +6,168 +13%
Rafferty Asset Management
71
Rafferty Asset Management
New York
$840K +$853K +50,259 New
BC
72
Brinker Capital
Pennsylvania
$690K +$17.5K +1,033 +3%
UBS AM
73
UBS AM
Illinois
$658K +$10.7K +630 +2%
FDCDDQ
74
Federation des caisses Desjardins du Quebec
Quebec, Canada
$626K +$3.31K +195 +0.5%
WCM
75
Weld Capital Management
New York
$600K +$610K +35,934 New
1 2
3
4 5

AIMT Hedge Fund Activity: Q2 2020 in Review

165 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Aimmune Therapeutics (AIMT) for Q2 2020, worth a combined $824M — up 16% from $712M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new AIMT positions and 22 closed out — a net gain of 4 holders — while 72 added to existing stakes and 37 trimmed.

The largest buyer was State Street, adding an estimated $25.9M. The largest seller was Victory Capital Management, cutting an estimated $28.9M.

  • 165 institutional investors held Aimmune Therapeutics (AIMT) as of Q2 2020, up from 161 in Q1 2020.
  • Funds reported $824M of Aimmune Therapeutics stock for Q2 2020, up 16% quarter-over-quarter.
  • 26 funds opened new Aimmune Therapeutics positions in Q2 2020 and 22 closed out, a net change of +4 holders.
  • The largest Aimmune Therapeutics buyer in Q2 2020 was State Street, an estimated $25.9M added.
  • The largest Aimmune Therapeutics seller in Q2 2020 was Victory Capital Management, an estimated $28.9M sold.

Based on aggregated 13F filings for Q2 2020.